Myocardial infarction in a human causes the death of billions of cardiomyocytes. The heart's limited capacity to regenerate these lost cardiomyocytes leads to compromised cardiac function and high morbidity and mortality. As a result, there has been intense interest in developing treatments to reduce or reverse myocardial injury. A number of strategies have been proposed for regenerative cardiovascular therapeutics, including transplantation of cells expanded ex vivo, delivery of therapeutic genes on naked DNA plasmids or viral vectors, and administration of recombinant proteins. Thus far, these approaches have had mixed results. Cell-based therapies have shown limited long-term engraftment and low efficacy. Genebased methods have been hampered by poor control of dosage and duration, low gene-transfer efficiency, risk of genomic integration and associated tumorigenesis, and antiviral immune responses. Recombinant-protein approaches have been characterized by fleeting protein half-lives, poor targeting to the heart and complications due to systemic release. modRNA, in which one or more nucleotides is replaced by modified nucleotides, represents a potential alternative. Previous work has shown that modRNA mediates highly efficient, transient protein expression in vitro and in vivo without eliciting an innate immune response [1] [2] [3] [4] [5] [6] . We therefore hypothesized that modRNA might provide an effective means to control the spatial and temporal delivery of gene products to enhance tissue repair or regeneration after injury.
A r t i c l e s
Myocardial infarction in a human causes the death of billions of cardiomyocytes. The heart's limited capacity to regenerate these lost cardiomyocytes leads to compromised cardiac function and high morbidity and mortality. As a result, there has been intense interest in developing treatments to reduce or reverse myocardial injury. A number of strategies have been proposed for regenerative cardiovascular therapeutics, including transplantation of cells expanded ex vivo, delivery of therapeutic genes on naked DNA plasmids or viral vectors, and administration of recombinant proteins. Thus far, these approaches have had mixed results. Cell-based therapies have shown limited long-term engraftment and low efficacy. Genebased methods have been hampered by poor control of dosage and duration, low gene-transfer efficiency, risk of genomic integration and associated tumorigenesis, and antiviral immune responses. Recombinant-protein approaches have been characterized by fleeting protein half-lives, poor targeting to the heart and complications due to systemic release. modRNA, in which one or more nucleotides is replaced by modified nucleotides, represents a potential alternative. Previous work has shown that modRNA mediates highly efficient, transient protein expression in vitro and in vivo without eliciting an innate immune response [1] [2] [3] [4] [5] [6] . We therefore hypothesized that modRNA might provide an effective means to control the spatial and temporal delivery of gene products to enhance tissue repair or regeneration after injury.
The fetal and post-natal mammalian heart contains a diverse set of endogenous cardiovascular progenitors [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , but native expansion, mobilization and differentiation of progenitors in vivo are inadequate to restore myocardial function after injury 18 , and inducing these processes for therapeutic benefit has proved difficult. Paracrine factors play key roles in regulating progenitor cell activity in heart development, and recent studies have likewise implicated paracrine factors in promoting cardiac repair and regeneration after myocardial infarction in experimental model systems 14, 16, 19 . In part, paracrine factors promote heart regeneration by stimulating the cardiomyogenic activity of poorly defined endogenous heart progenitors 14, 19, 20 . Given that native paracrine signals are often transient and precisely regulated in time and space, we further hypothesized that the pulse-like expression profile of modRNA might be well suited to delivering paracrine-factor Modified mrNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction A r t i c l e s signals that modulate heart progenitor activity and thereby promote heart repair or regeneration.
To test these hypotheses, we studied the kinetics and efficacy of modRNA-mediated gene transfer in a mouse myocardial infarction model. Previous work has shown that epicardial heart progenitors are activated within 48 h after mouse myocardial infarction and are amplified in a thickened epicardial layer at the surface of the heart. However, these cells are not mobilized to enter the myocardium and differentiate toward cardiovascular lineages as they do in the fetal heart 13, 15, 21 , but rather remain on the heart surface and differentiate largely into fibroblasts and myofibroblasts. For initial proof-ofconcept experiments, we studied modRNA encoding the VEGF-A protein, a potent angiogenic factor. Based on its angiogenic activity, VEGF-A has been proposed as a therapeutic agent to improve myocardial outcome after ischemic injury (Supplementary Appendix and Supplementary Tables 1 and 2). Previous human and animal studies of delivery of VEGF-A after injury using naked DNA plasmids, recombinant proteins and engineered viruses showed limited efficacy after myocardial infarction, but these negative results may have been due to suboptimal delivery and/or antiviral immune responses [22] [23] [24] [25] . Temporal and spatial control of VEGF-A expression is likely to be critical for its therapeutic efficacy, as two independent groups showed that prolonged exposure of normal muscle to VEGF-A caused excessive vascular permeability [26] [27] [28] . Furthermore, our recent work identified a novel role for VEGF-A as a cell fate switch for multipotent ISL1 + human heart progenitors, driving their differentiation away from cardiac muscle and toward the endothelial lineage 29 . The potential activity of VEGF-A on endogenous cardiac progenitors has not been studied in vivo or in the context of myocardial injury.
Here we asked whether in vivo delivery of VEGF-A modRNA given at the time of epicardial progenitor activation after myocardial infarction would stimulate their mobilization or modulate their differentiation. We found that modRNA mediates 'pulse-like' expression of VEGF-A and is superior to plasmid DNA in reducing infarct size, enhancing myocardial perfusion and improving survival. In part, this effect was due to a previously unknown effect of VEGF-A on epicardial progenitors. VEGF-A modRNA amplified these progenitors, mobilized their migration into the myocardium and redirected their differentiation toward cardiovascular lineages. These results indicate that modRNA gene transfer drives in vivo heart progenitor cell fate to enhance cardiac repair.
RESULTS
Pulse-like kinetics of modRNA gene delivery to heart and skeletal muscle We evaluated the suitability of modRNA for gene transfer to heart and skeletal muscle-tissues that have been historically difficult to transfect. Notably, modRNA transfected primary fetal human, neonatal mouse, and adult rat cardiomyocytes or adult mouse skeletal myotubes with high efficiency (89%, 72%, 68% and 100%, respectively; Supplementary Fig. 1 ) and minimal toxicity (~80% cell survival, comparable to transfection vehicle control). This high efficiency represents a 10-to 40-fold increase compared to typical transfection efficiencies attained using nonviral DNA-mediated transfection 22, 30 . modRNA likewise mediated efficient protein production in cardiac cells in vivo. Direct, single, intramyocardial injection of luciferase (Luc) modRNA yielded a robust bioluminescent signal indicative of dose-and time-dependent luciferase protein expression localized to the injection site (Fig. 1a-c) . Luc was immediately expressed and reached high levels after only 3 h, peaked at 18 h and returned to 
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A r t i c l e s baseline at 144-150 h (Fig. 1c) . These kinetics differed considerably from luciferase DNA, which peaked at 72 h and retained a high signal for more than 10 d after injection. To examine cardiac cell types transduced by modRNA, we injected Cre recombinase DNA plasmid or modRNA into Rosa26-lox-stop-lox-LacZ (R26 fsLacZ ) mouse hearts, followed by 5-bromo-4-chloro-3-indolyl-β-d-galactoside (X-gal) staining for Cre-activated β-galactosidase (blue stain, Fig. 1d-j) . Whereas using DNA plasmids resulted in infrequent cell transfection (Fig. 1e-g ), the vast majority of cells in the injection region were transfected by modRNA, including endothelial cells (~90%), cardiomyocytes (~80%) and smooth muscle cells (~90%) (Fig. 1h-j) . A single injection of modRNA into the cardiac apex efficiently transfected a substantial area of myocardium (~25% of the left ventricle), a level of transfection that was at least ten times greater than that achieved by injection of naked plasmid DNA (Fig. 1k) . Similarly efficient in vivo modRNA transfection was observed in skeletal muscle (Supplementary Fig. 2 ).
VEGF-A modRNA improves myocardial outcome after myocardial infarction
The pulse-like kinetics of modRNA gene delivery led us to hypothesize that modRNA might be an effective means to deliver paracrine factors that could alter progenitor cell fate and thereby durably modify organ injury responses. We therefore set out to determine whether VEGF-A modRNA has beneficial activity in myocardial infarction, and we compared its performance to traditional, nonviral, VEGF-A delivery by plasmid DNA. First, we examined the kinetic profile of VEGF-A expression after VEGF-A modRNA administration in vivo and in vitro. Previous work established that cardiac VEGF-A ectopic expression does not elevate VEGF-A protein levels in serum 31 . In our in vitro experiments, however, cardiac cells transfected with VEGF-A modRNA translated and secreted VEGF-A protein with pulse-like kinetics that peaked rapidly and declined to basal levels after 2-3 d (Fig. 1l) . In contrast, transfection with VEGF-A DNA plasmid induced a much broader secretion profile that peaked at a lower level at 3 d and gradually declined, with protein levels remaining above baseline at day 10. A r t i c l e s Next, we evaluated the toxicity and immunogenicity of VEGF-A modRNA in vitro and in vivo. VEGF-A modRNA induced greater VEGF-A protein secretion than VEGF-A mRNA ( Supplementary  Fig. 3a ). Unlike mRNA, modRNA did not cause apoptosis or upregulation of RIG-1, INF-α or INF-β, hallmarks of the innate immune response ( Supplementary Fig. 3b-c) . VEGF-A modRNA likewise exhibited minimal immunogenicity when delivered to skeletal muscle in vivo (Supplementary Fig. 3c ). In addition, DNA plasmid delivery in vivo into cardiac muscle upregulated INF-β and RIG-1. These results are consistent with prior studies that demonstrated low modRNA toxicity and immunogenicity [1] [2] [3] [4] [5] 32 and immunogenicity of DNA plasmid 33, 34 . Together, these data show that modRNA is an efficient and nontoxic approach for transient, highly efficient and localized gene delivery to heart and skeletal muscle.
To assess the efficacy of VEGF-A modRNA in the mouse myocardial infarction model, we administered it at the time of coronary artery ligation by direct intramyocardial injection into the ischemic region. VEGF-A modRNA stimulated formation of systemically perfused vessels in the area of injection (Fig. 2a) . Both VEGF-A modRNA and VEGF-A DNA reduced infarct size and apoptotic cell frequency, and increased capillary density at 1 and 4 weeks after myocardial infarction ( Fig. 2b , P ≤ 0.05; Supplementary Fig. 4 ). These beneficial effects required VEGF-A signaling through its canonical receptor KDR (also known as VEGFR2), because they were blocked by either SU5614 or PTK787, specific small-molecule inhibitors of KDR ( Fig. 2c ; P ≤ 0.05).
Although both VEGF-A modRNA and DNA increased myocardial capillary density and reduced infarct size and cell death, the vessels formed by these treatments were functionally different. In VEGF-A DNA-treated hearts, vessels showed excessive permeability as demonstrated by extravasation of 70-kd dextran beads ( Fig. 2d-f ). In contrast, vessels in VEGF-A modRNA-treated hearts did not show this abnormal vascular permeability ( Fig. 2d-f) . The difference in vascular permeability was readily apparent on inspection of hearts: VEGF-A modRNA-treated hearts were similar in shape to control hearts, whereas VEGF-A DNA-treated hearts displayed obvious edema (Fig. 2g) . This difference in vessel function was likely due to prolonged exposure to VEGF-A with DNA-mediated gene transfer, as increased vascular permeability is a known consequence of lengthy VEGF-A expression [35] [36] [37] . To further evaluate the importance of expression kinetics on outcome, we administered bevacizumab (Avastin), a neutralizing antibody specific for transfected human VEGF-A starting at 3 d after myocardial infarction. Bevacizumab did not detectably affect VEGF-A modRNA activity in increasing vessel density ( Fig. 2d-g ) but it blocked vessel induction by VEGF-A DNA, consistent with the differing expression kinetics of each modality. On the other hand, bevacizumab reduced the abnormal vascular permeability and edema induced by VEGF-A DNA. These data indicate that the rapid, brief pulse of VEGF-A delivered by modRNA stimulated growth of functional vessels, whereas the more prolonged VEGF-A expression delivered by DNA stimulated formation of leaky vessels.
We next evaluated the effect of VEGF-A modRNA and DNA on short-term survival after myocardial infarction (Fig. 3a) . Although VEGF-A DNA augmented vessel number, it caused increased mortality compared to vehicle controls (P = 0.02 versus vehicle control), consistent with earlier reports 28 . This detrimental effect was likely due to increased vascular permeability and cardiac edema from prolonged VEGF-A exposure, because bevacizumab blockade of human VEGF-A beginning on post-myocardial infarction day 3 restored mortality to control levels (P = 0.04 in presence versus absence of bevacizumab). Unlike VEGF-A DNA, VEGF-A modRNA did not have an adverse effect on short-term survival, and, consistent with VEGF-A modRNA expression kinetics, this was not significantly changed by bevacizumab given 3 d after myocardial infarction (Fig. 3a) . Together, these data point to the importance of VEGF-A expression kinetics mediated by different gene expression systems in determining their biological effect (Supplementary Table 3) .
To assess the long-term effect of VEGF-A modRNA on outcome after myocardial infarction, we monitored the survival of control mice and mice treated with VEGF-A modRNA for a year after myocardial infarction. VEGF-A DNA-treated mice were not included in this long-term study because of their poor survival in the first month following MI. In the control group, the 1-month survival was ~60%, similar to that in other reported studies [38] [39] [40] . Survival was significantly higher in the VEGF-A modRNA group than in controls at this late end point ( Fig. 3b ; P = 0.04; n = 14). The beneficial effect of VEGF-A modRNA on survival was reflected in its effect on cardiac function, as determined by cardiac magnetic resonance imaging (MRI) measurement of cardiac ejection fraction (EF; Fig. 3c,d) . At day 1 following myocardial infarction, EF was reduced to a similar extent in 
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A r t i c l e s control and VEGF-A modRNA groups, indicating equivalent severity of myocardial injury (Fig. 3d) . At 21 d after myocardial infarction, EF was better preserved in the VEGF-A modRNA group ( Fig. 3d ; P = 0.001, n = 4; Supplementary Movies 1-3). Consistent with declining heart function in controls compared to VEGF-A modRNA treatment, heart rate increased between days 1 and 21 after myocardial infarction in controls, and this effect was blocked by VEGF-A modRNA (Supplementary Fig. 5 ). Other MRI indices were not significantly different between groups (Supplementary Fig. 5 ). MRI assessment at later time points was not done because excess mortality in the control group would have introduced strong survivor bias. Collectively these data indicate that VEGF-A modRNA has sustained beneficial effects on myocardial outcome and on long-term survival after myocardial infarction.
VEGF-A modRNA activates epicardial cardiac progenitor cells through KDR To further investigate mechanisms that underlie the beneficial activity of VEGF-A modRNA, we measured the expression of known cardiovascular progenitor and differentiated cell lineage markers in peri-infarct tissue of control and VEGF-A modRNA-treated hearts.
qRT-PCR analysis showed upregulation of the cardiomyocyte marker Tnnt2 and the endothelial cell markers Pecam1 and Kdr ( Fig. 4a and Supplementary Fig. 6 ). Among cardiac progenitor markers, Wilms' tumor gene 1 (Wt1) was highly upregulated by VEGF-A modRNA compared to control treatment, whereas other heart progenitor markers, such as Isl1 (refs. 7-11) and Nkx2-5, were not substantially changed ( Fig. 4a and Supplementary Fig. 6 ). In the heart, Wt1 is a marker of an epicardial progenitor population that has an important role in heart injury responses 16 . Upregulation of Wt1 was confined to the heart and was not observed in other compartments including those that might be sources of blood-borne cells (Supplementary Fig. 7) . Wt1 upregulation by VEGF-A modRNA suggested that the VEGF-A pulse affected the epicardial progenitor population. We confirmed a marked increase in WT1 + cells in the peri-infarct region by immunohistochemistry (Fig. 4b) . Notably, this amplification of WT1 + cells by VEGF-A modRNA required activation of epicardial cells by injury, as it was not observed in VEGF-A modRNA-treated, sham-operated hearts (Fig. 4b) . KDR inhibition by either SU5614 or PTK787 blocked the effect of VEGF-A modRNA (Fig. 4c) , indicating that KDR action requires canonical VEGF-A signaling through the KDR receptor. These results were confirmed in an unbiased and independent fluorescenceactivated cell sorting (FACS)-based approach that took advantage of the Wt1 GFPCre mouse line, in which a GFP-Cre fusion protein is knocked into the endogenous Wt1 locus 15 . Consistent with quantification of WT1 + cells by immunohistochemistry, FACS-based quantification of A r t i c l e s the number of WT1 + cells by GFP signal showed that myocardial infarction alone substantially expanded this cell population (Fig. 4d) , as we reported previously 16 . VEGF-A modRNA, but not Luc modRNA, further strongly amplified this population by about fourfold. Again, this effect was blocked by KDR inhibitors SU5614 and PTK787. To determine whether VEGF-A acts directly on WT1 + epicardial progenitors to drive their amplification, we measured the abundance of KDR receptors on these cells by FACS (Fig. 4e) . In sham-operated hearts, WT1 + cells expressed low levels of the KDR receptor (mean KDR fluorescence intensity was about twofold above isotype control background). WT1 + cell expression of the KDR receptor increased dramatically (about sixfold) after myocardial infarction, and VEGF-A modRNA treatment further upregulated KDR expression by 5.5-fold, indicating a positive-feedback response in which VEGF-A reinforces KDR expression, as previously noted in endothelial cells 41 . Upregulation of KDR after myocardial infarction coincides with the general activation of numerous epicardial genes after injury 16 and likely accounts for the requirement of myocardial infarction to enable WT1 + epicardial cells to respond to VEGF-A modRNA (Fig. 4b) . To further determine whether VEGF-A acts directly on post-myocardial infarction WT1 + epicardial cells, we purified these cells by FACS and measured their proliferation in response to recombinant VEGF-A (Fig. 4f) . VEGF-A increased proliferation of cultured WT1 + epicardial cells, and KDR inhibition powerfully blocked their proliferation. These data indicate that VEGF-A acts directly through KDR on activated, post-myocardial infarction WT1 + epicardial progenitors.
VEGF-A modRNA induced WT1 + epicardial progenitor differentiation into endothelial cells in vitro
During heart development, WT1 + epicardial progenitors undergo an epithelial-to-mesenchymal transition. The resulting epicardiumderived cells (EPDCs) migrate into the myocardium and predominantly differentiate into fibroblasts and smooth muscle cells. Infrequently, EPDCs contribute to the endothelial lineage 15, 42 , and they have also been found to differentiate into cardiomyocytes 13, 17, 42 . VEGF-A modRNA increased capillary density and upregulated endothelial markers in peri-infarct tissue (Fig. 2b) . We hypothesized that VEGF-A might alter the fate of the WT1 + epicardial progenitors and enhance their endothelial differentiation. qRT-PCR analysis of FACS-purified, post-myocardial infarction, WT1 + epicardial progenitors indicated that VEGF-A modRNA strongly upregulated expression of endothelial markers Pecam1 and Kdr (Fig. 5a) . VEGF-A stimulation of endothelial differentiation of epicardial progenitors was further demonstrated by culturing FACS-purified, post-myocardial infarction, Wt1 + cells for 7 d in the presence or absence of recombinant VEGF-A. Analysis of marker genes by qRT-PCR revealed that VEGF-A stimulation strongly upregulated endothelial markers VE-Cadherin, Pecam1 and Kdr (Supplementary Fig. 8a ). This result was corroborated by FACS analysis, which showed that VEGF-A treatment markedly increased the frequency of KDR + /VE-cadherin + endothelial cells (68% versus 14%; Supplementary Fig. 8b) , and by immunofluorescence imaging, which demonstrated co-expression of VE-cadherin and GFP (expressed from Wt1 GFPCre ) in cultures stimulated by VEGF-A (Supplementary Fig. 8c) .
We further tested the hypothesis that VEGF-A influences WT1 + epicardial progenitor cell lineage decisions using an in vitro clonal assay. FACS-purified, post-myocardial infarction, WT1 + epicardial cells were individually plated in 96-well dishes, clonally expanded and assessed for differentiation into the major cardiac lineages in the presence or absence of recombinant VEGF-A by qRT-PCR (Fig. 5b) . This assay demonstrated the multipotency of WT1 + epicardial progenitors at the clonal level (Fig. 5c) . VEGF-A treatment for 7 d increased the fraction of clones that were positive for the endothelial marker VE-Cadherin from 12% to 52% (Fig. 5c ). To further demonstrate that this was a clonal event rather than polyclonal contamination of endothelial cells, we subcloned a clone that was initially VE-Cadherin negative in the absence of VEGF-A and repeated the clonal differentiation assay. VEGF-A again strongly stimulated differentiation toward an endothelial fate (24% versus 0%, Fig. 5d ). These clonal assays confirm the multipotency of WT1 + epicardial progenitor cells, and demonstrate at the clonal level that VEGF-A biases epicardial progenitor fate decisions toward the endothelial lineage.
In summary, these studies identify epicardial progenitors as a target for VEGF acting as a vasculogenic cell fate switch, in addition to its (Fig. 6a-e and Supplementary  Fig. 9 ). VEGF-A modRNA increased the number of EPDCs fourfold (Fig. 6b) . The fraction of PECAM1 + cells was 26% greater in VEGF-A modRNA versus Luc modRNA hearts (44% versus 18%). Therefore, we estimate that ~23% (6% of Wt1 CreERT2 -labeled EPDCs / 26% total endothelial cells) of the VEGF-A-stimulated increase in PECAM1 + cells arose from EPDCs. This result was supported by qRT-PCR of FACS-purified EPDCs, which showed that VEGF-A modRNA increased expression of Pecam1 and Kdr (Fig. 6c) . Moreover, EPDCs in the VEGF-A modRNA group upregulated the cardiomyocyte marker Tnnt2, suggesting that VEGF-A enhanced EPDC differentiation toward the cardiomyocyte lineage. Confocal analysis of immunostained sections further substantiated these conclusions. In controls without injury or with myocardial 16 ( Supplementary Fig. 9 ). In contrast, myocardial infarction and VEGF-A modRNA mobilized EPDCs so that they migrated into the myocardium (Supplementary Fig. 9 ) and increased differentiation toward the endothelial lineage (58% with VEGF-A modRNA versus 16% with Luc modRNA; Fig. 6d,e) . We also detected EPDCs that co-expressed the cardiomyocyte marker TNNI3 in VEGF-A modRNA hearts, but not in controls (5% versus 0%, respectively; Fig. 6d,e) . It is unlikely that this result was due to VEGF-A-induced upregulation of Wt1 (and therefore the CreERT2 lineage tracer) in cardiomyocytes, as qRT-PCR indicated that VEGF-A had no effect on adult cardiomyocyte Wt1 expression (Supplementary Fig. 10 ). Furthermore, tamoxifen labeling was done before either myocardial infarction or VEGF-A modRNA treatment, and the level of tamoxifen-independent Cre activity in myocardial infarction and VEGF-A modRNA-treated hearts was trivial (0.005% of cardiomyocytes and 0.003% of endothelial cells were GFP + ). To confirm our results using an independent system that did not critically depend on Wt1-driven marker alleles, we used a Cre modRNAcontaining biocompatible gel to selectively label and trace the fate of epicardium-derived cells in the adult heart (Fig. 6f) . When applied to R26 mTmG hearts, Cre modRNA gel selectively labeled cells in the epicardial layer (Fig. 6g) . We tested the kinetics of gene transfer by means of modRNA gel by applying Luc modRNA gel onto the hearts of CFW strain mice (Supplementary Fig. 11a,b) . Luciferase bioluminescence was detected at near-peak levels by 3 h and peak levels at 24 h, and it was no longer detectable at 72 h. Similarly, Cre modRNA gel expressed Cre protein in cells confined to the epicardial layer 2 d after gel application, but Cre protein was no longer detectable at 14 d (Supplementary Fig. 11c ).
Based on these data, we developed a Cre modRNA gel-based prelabeling strategy (Fig. 6f) that minimized the possibility of nonepicardial labeling in the complex environment induced by the myocardial infarction. We applied Cre modRNA gel to the heart to label epicardial cells, waited 2 weeks for decay of Cre activity, and then performed LAD ligation and concurrent myocardial injection of VEGF-A or Luc modRNA into the infarct region. One week later, we assessed the fate of Cre modRNA-labeled EPDCs by confocal analysis of immunostained cryosections. Consistent with the Wt1 CreERT2 labeling result, EPDCs remained in the epicardial layer in control hearts with sham operations or hearts with myocardial infarction plus Luc modRNA. In contrast, myocardial infarction plus VEGF-A modRNA mobilized EPDCs from the epicardial layer and allowed their migration into the myocardium (Fig. 6g and Supplementary Fig. 12 ). EPDCs co-expressed smooth muscle, endothelial and cardiomyocyte lineage markers (Fig. 6h and Supplementary Fig. 12) . Quantification of the percentage of EPDCs expressing each lineage marker showed that VEGF-A modRNA directed EPDCs toward an endothelial fate (48% versus 9%), and led to a small but reproducible subset of EPDCs co-expressing cardiomyocyte markers (Fig. 6g-i) . Collectively, the Wt1 CreERT2 and Cre modRNA gel fate mapping experiments demonstrate through two independent approaches that VEGF-A modRNA alters EPDC fate in the postnatal heart, driving EPDC differentiation into endothelial cells and potentially to cardiomyocytes.
DISCUSSION
Our study advances an approach to solid-organ repair and regeneration in which delivery of appropriate signal(s) at the right time and place modifies endogenous progenitor cell activity and thereby promotes longstanding therapeutic benefits. We show that modRNA is an effective, robust approach to implement this approach. modRNA avoids several of the apparent problems that have arisen with conventional cardiac gene therapy vectors 30, 44 , including lack of genomic integration, persistence of expression, immunogenicity, difficulty in scalability and production, need for life-long monitoring for tumorigenesis and other adverse clinical outcomes, and the potential for vector escape into the systemic circulation and long-term expression elsewhere in the body. For these reasons, modRNA has considerable translational potential.
One of the keys to paracrine signal therapeutics is to deliver a transient, strong signal at a time and place that coincides with initial activation of an endogenous progenitor pool. As shown in this study, a transient pulse delivered in this manner can achieve long-term benefit through modification of progenitor cell activity and fate. Specifically, we demonstrated that a single intramyocardial injection of VEGF-A modRNA improved myocardial outcome and survival after myocardial infarction. This salutary response was due to improved formation of functional vessels in the peri-infarct region, which is associated with altered activity of epicardial progenitors. Pulse-like VEGF-A expression after myocardial infarction amplified the WT1 + epicardial progenitor pool and enhanced their differentiation toward the endothelial lineage (Fig. 7) , forming a substantial subset of the additional endothelial cells generated under VEGF-A stimulation. This VEGF-A effect on epicardial progenitors is reminiscent of the effect of VEGF-A on multipotent Isl1 heart progenitors that we recently reported 29 , and indeed VEGF-A may similarly affect other cardiac progenitor populations. The unique kinetics of modRNA delivery were required to obtain benefit, as it permitted pulse-like VEGF-A delivery at precisely the time that myocardial injury activates epicardial cells from their quiescent state in the normal heart. The transient nature of VEGF-A modRNA delivery was also crucial, as sustained VEGF-A delivery by DNA injection led to adverse effects on vascular function. EDPC lineage tracing using several different genetic labels has indicated that a subset of EPDCs differentiate into cardiomyocytes under certain conditions in the developing and adult heart 6, 12, 13, 45, 46 . Consistent with prior studies 15, 16 , we found that adult EPDCs have little native potential to differentiate toward the cardiomyocyte lineage. However, VEGF-A stimulation appeared to increase cardiomyocyte differentiation to consistently detectable, albeit low, levels. We confirmed this result using an independent lineage tracing system, bolstering the evidence that EPDCs differentiate into cardiomyocytes. However, given the pitfalls and limitations of genetic lineage tracing approaches 47, 48 and the lack of cardiomyocyte differentiation in the in vitro clonal assay (which might be attributable to inadequacies of 
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A r t i c l e s the in vitro culture system), additional studies are needed to further support this conclusion. The number of cardiomyocytes formed by EPDCs was reproducible but low and likely not sufficient to account for the therapeutic benefit of VEGF-A modRNA. Nevertheless, this finding suggests that additional paracrine signals might be identified that will achieve differentiation of EPDCs to cardiomyocytes at therapeutically meaningful levels.
METHODS
Methods and any associated references are available in the online version of the paper. Epicardial lineage tracing using modRNA gel. The Cre modRNA gel, with a mixture of Cre modRNA (10 µl of modRNA at 20 µg/µl)), lipofectamine (30 µl), and 0.05% polyacrylic acid (10 µl; Sigma), was painted on the surface of the Rosa26 (R26) mTmG hearts 2 weeks before LAD ligation and injection of VEGF-A or Luc modRNA. VEGF-A-or Luc modRNA-treated hearts were assessed for expression of GFP and different myocardial markers to examine the cell fate of the EPDC derivatives 7 d after myocardial infarction.
Mice. Wt1 GFPCre/+ , Wt1 CreERT2 , R26 fsLacZ and R26 mTmG alleles have been described previously [15] [16] [17] 43, 49 . Genetically engineered mice were in a mixed C57BL6/CFW background and both male and female mice were used. Tamoxifen-free base (Tam) was dissolved in sunflower seed oil at 12 mg/ml by sonication. 0.12 mg/g body weight Tam was administered to adult mice twice weekly for 3 weeks to induce CreERT2-mediated recombination. One week after completion of Tam dosing (to allow Tam clearance), myocardial infarction was induced by ligation of the left anterior descending coronary artery as described below. Hearts were subsequently assessed using a combination of FACS, immunofluorescence and real-time-qPCR (RT-qPCR) analyses for GFP expression and myocardial markers after 7 d. Wt1 GFPCre was used for isolating Wt1 + progenitor cells by the Wt1-driven GFP marker. The fate of Wt1 + epicardial progenitors was determined using adult-stage irreversible labeling in the Wt1 CreERT2/+ øR26 mTmG model. Mice that were Luc modRNA-treated after Tam induction in the presence of myocardial infarction were used as controls.
To examine "leaky" CreERT2 activity that might occur under stress in the absence of Tam, mice were treated with sunflower seed oil without Tam before myocardial infarction and subsequently underwent myocardial infarction and VEGF-A modRNA or control treatments in parallel with Tam-treated mice. Wild-type were CFW strain (only males). Animals were not randomized, but procedures were done with researchers blinded to genotype and treatment group. All animals that started an experimental protocol and that survived to the measurement point were included. All mice housing and handling were performed in accordance with protocols approved by Institutional Animal Care and Use Committees at Massachusetts General Hospital or Children's Hospital Boston or Harvard University.
Cell culture. Adult CFW or WT1 GFPCre/+ hearts were digested using the Neomyt Cardiomyocyte Isolation kit (Cellutron) to achieve a single-cell suspension of adult mouse cardiac cells, according to the manufacturer's instructions. Adult mouse cardiac cells were cultured in Mesenchymal Stem Cell Growth Medium (Lonza) containing 10% FBS. Primary cultures of human fetal cardiomyocytes (obtained from Advanced Bioscience Resources, Inc. at gestational age 20 weeks) were prepared from human fetal ventricles as described before 9 . Briefly, cardiomyocytes were dissociated by means of repeated (6 ×) enzymatic digestion with collagenase II solution (Life Technologies) at 37 °C. Dissociated cells were pelleted (30 g × 2 min) and plated at a density of 1 × 10 5 cells/cm 2 on 35-mm culture dishes with 2 ml of culture medium (3:1 DMEM: M-199 medium with 5% FCS and 10% neonatal calf serum). Pre-plating of seeded cells onto 100-mm culture dishes to remove noncardiomyocytes (for three consecutive days) yielded cultures containing ~80% cTnT heavy chainpositive cardiac myocytes. Mouse neonatal hearts were dissociated to single cells by collagenase II (Sigma) as described previously 16 . Mouse neonatal cardiomyocytes were cultured in DMEM containing 5% FBS, 10% horse serum and 1 µg/ml insulin. Rat adult cardiomyocytes were a kind gift from R. Liao, and isolation and culture methods have been described previously 50 . All cell lines were found negative for mycoplasma contamination. The secretion of VEGF-A protein was measured using supernatant of mouse adult cardiac cells after transfection with VEGF-A modRNA or DNA or RNA using ELISA (R&D systems). Cell transfection efficiency and survival after modRNA transfection was determined as follows: 4 wells were transfected with each different concentration of modRNA GFP (with 0, 0.3, 1 or 3 µg per 10 5 cells in a well of a 6-well plate). 16 h after transfection of cardiac cells, 2 wells from each treatment were trypsinized and stained for trypan blue. The percentage of intact cells was calculated as the number of trypan blue-negative cells per treatment well/number of trypan blue-negative cells per well without any treatment *100. To determine transfection efficiency, the two remaining wells were stained for TNNT2 (red) and GFP (green), and double-positive cells were measured using ImageJ software.
Wt1-GFP + cell isolation and in vitro clonal assays. WT1 + epicardial progenitors were isolated from the heart explants of WT1 GFPCre/+ mice 7 d after myocardial infarction. Cardiac cells (nonmyocytes) were allowed to expand from heart explant cultures. As a control, hearts from uninjured Wt1 GFPCre/+ or Wt1 CreERT2/+ øR26 mTmG mice treated either with vehicle or hVEGF-A modRNA were also analyzed. After 1-2 weeks, cells were FACS sorted (FACS Aria III) for GFP + cells (WT1 + ). Single cells or pooled cells of WT1 + epicardial progenitors were plated in a fibronectin-coated (5 ng/ml for 2 h at 37 °C) 96-well plate or 1 well of a 12-well plate, respectively. Cell proliferation of the WT1 + epicardial progenitors was assessed in the presence or absence of VEGF-A (50 ng/ml) or different KDR inhibitors, including SU5614 or PTK787 (10 nM/l) or DMSO control at different time points (4, 8 and 14 d) . Media were changed every 3 d. Calibration curve of DMSO and KDR inhibitors indicate that the optimal range (ratio of cell death of vehicle treatment (DMSO control) to KDR inhibitors) of using these inhibitors in vitro is 4-10 nmol/l. Cells were counted using an automated cell counter (Invitrogen).
For clonal assays, epicardial explants from Wt1 GFPCre/+ myocardial infarction mice were cultured as described 17 . Explant outgrowths were then dissociated and WT1 + epicardial cells were FACS sorted. Single sorted cells were deposited into fibronectin-coated 96-well plates and clonally expanded in the presence or absence of VEGF-A (100 µg/ml) for 7-14 d before examination for their cell fate change in vitro. For FACS analyses, sorted cells were incubated with fluorochrome-conjugated primary antibodies at 4 °C for 30 min followed by three washes with PBS/2% FBS and resuspended in Hank's balanced salt solution. Flow cytometric analyses were done using a BD FACSCanto npg were stained for skeletal muscle myosin heavy chain (Primary antibody: antiskeletal myosin type II (fast-twitch) 1:200 and anti-skeletal myosin type I (slow-twitch) 1:100, Sigma. Secondary: goat anti-mouse IgG Alexa-555 conjugate (Molecular Probes) 1:250), 10 µg/ml Hoechst (Invitrogen) and rabbit anti-GFP Alexa-488 1:200 (Invitrogen). Pictures were taken from the whole well using the Celigo cytometer (Cyntellect) under blue, red and green channels. Cell viability was measured by quantifying the total number of nuclei in the transfected wells 16 h after transfection and normalizing them to the total number of nuclei in the nontransfected wells. Total number of nuclei in the whole wells was quantified using a modified ImageJ macro.
